KYMR Stock Overview A biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Kymera Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Kymera Therapeutics Historical stock prices Current Share Price US$40.66 52 Week High US$53.27 52 Week Low US$22.35 Beta 2.17 1 Month Change -9.60% 3 Month Change -18.65% 1 Year Change 58.21% 3 Year Change -34.18% 5 Year Change n/a Change since IPO 22.25%
Recent News & Updates See more updates
Kymera: Protein Degradation Could Drive Dupixent-Like Value Dec 07
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts Nov 04 Kymera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $49.990004 million. Nov 01
Kymera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million. Oct 31
Kymera Therapeutics, Inc. Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-In-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases Oct 25
Kymera Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 23
Kymera Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for KT-621, A First-In-Class, Oral Stat6 Degrader Oct 09
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors Oct 06 Kymera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $224.999632 million. Aug 21
Kymera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.
Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results Aug 11
Kymera Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 31
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up Jul 14
Kymera Therapeutics, Inc. Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy Jul 09
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of Stat3 Degrader Kt-333 At Eha Annual Meeting Jun 15
Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being Jun 12
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting Jun 02
Kymera Therapeutics, Inc. Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting May 23
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of Stat3 Degrader KT-333 At EHA Annual Meeting May 15
Consensus EPS estimates upgraded to US$2.90 loss, revenue downgraded May 09
We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth May 03
Kymera Therapeutics, Inc. Provides Business Highlights and Updates on Its Pipeline of Protein Degraders May 03
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 03
Kymera Therapeutics, Inc., Annual General Meeting, Jun 18, 2024 Apr 26
Price target increased by 7.0% to US$51.07 Apr 23
Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting Apr 10
Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith Mar 21
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs At the American Academy of Dermatology Annual Meeting Mar 08
New minor risk - Insider selling Mar 07
Consensus revenue estimates increase by 45% Mar 03
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43 Feb 25
New major risk - Revenue and earnings growth Feb 25
Full year 2023 earnings: EPS and revenues exceed analyst expectations Feb 24
Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking Feb 17
Kymera Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Feb 16
Chief Medical Officer notifies of intention to sell stock Feb 12
Independent Director notifies of intention to sell stock Jan 26
Price target increased by 8.3% to US$43.00 Jan 14
Price target increased by 7.3% to US$42.77 Jan 10
New minor risk - Shareholder dilution Jan 07 Kymera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $274.999133 million. Jan 06
Kymera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $274.999133 million.
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up Dec 29
Kymera Therapeutics, Inc. Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting Dec 11
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656)p Dec 07
Kymera Therapeutics, Inc. Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-In-Class IRAK4 Degrader, in Nature Medicine Nov 15
Consensus revenue estimates decrease by 18%, EPS upgraded Nov 12
Consensus revenue estimates decrease by 12%, EPS upgraded Nov 09
We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully Nov 06
Kymera Therapeutics, Inc. to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting Nov 04
Price target decreased by 16% to US$47.47 Nov 03
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 03
Kymera Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656) Oct 28
Kymera Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 27
New minor risk - Share price stability Oct 26
Kymera Therapeutics, Inc. Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma Oct 17
New major risk - Revenue and earnings growth Oct 17
Kymera Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma Sep 19
Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts Aug 31
Consensus revenue estimates increase by 19% Aug 31
New major risk - Revenue and earnings growth Aug 04
Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation Aug 04
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 03
Kymera Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29
Kymera Therapeutics, Inc.(NasdaqGM:KYMR) dropped from Russell Small Cap Comp Value Index Jun 25
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials Jun 14
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Jun 11
Kymera Therapeutics, Inc. Presents Data Demonstrating Superior Efficacy of Kt-253, A Potent and Selective Heterobifunctional Mdm2 Degrader Jun 10
Kymera Appoints Jeremy Chadwick as Chief Operating Officer May 23
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up May 21
Kymera Therapeutics, Inc. Presents Clinical Data from the Phase 1 Trial of Irak4 Degrader, KT-474 (Sar444656), At the European Academy of Dermatology and Venereology Symposium May 19
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind May 05
We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely Apr 16
Consensus revenue estimates fall by 13% Mar 02
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 24
Kymera Therapeutics, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 02
Kymera Therapeutics, Inc. Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary Jan 05
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth Dec 28
Kymera Therapeutics, Inc. Announces Positive Clinical Results from the Patient Cohort Portion of Its KT-474 (IRAK4) Phase 1 Clinical Trial Dec 16
Kymera Therapeutics, Inc.' Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting Dec 13
Kymera Therapeutics, Inc. Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting Dec 12
Consensus revenue estimates fall by 20% Nov 10
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 04
Kymera Therapeutics, Inc. Announces Management Changes Nov 04
Kymera Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 21
Co-Founder exercised options to buy US$1.4m worth of stock. Oct 18 Shareholder Returns KYMR US Biotechs US Market 7D -3.5% -3.6% -2.4% 1Y 58.2% -2.7% 23.3%
See full shareholder returns
Return vs Market: KYMR exceeded the US Market which returned 23.3% over the past year.
Price Volatility Is KYMR's price volatile compared to industry and market? KYMR volatility KYMR Average Weekly Movement 7.5% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: KYMR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KYMR's weekly volatility (8%) has been stable over the past year.
About the Company Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus.
Show more Kymera Therapeutics, Inc. Fundamentals Summary How do Kymera Therapeutics's earnings and revenue compare to its market cap? KYMR fundamental statistics Market cap US$2.63b Earnings (TTM ) -US$167.47m Revenue (TTM ) US$87.56m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) KYMR income statement (TTM ) Revenue US$87.56m Cost of Revenue US$221.40m Gross Profit -US$133.84m Other Expenses US$33.64m Earnings -US$167.47m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.59 Gross Margin -152.85% Net Profit Margin -191.26% Debt/Equity Ratio 0%
How did KYMR perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 02:12 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Kymera Therapeutics, Inc. is covered by 27 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Zhiqiang Shu Berenberg Etzer Darout BMO Capital Markets Equity Research Tazeen Ahmad BofA Global Research
Show 24 more analysts 
